NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
Updated: Jun 22, 2022
Multiple Myeloma Research Consortium
NCT02199665: Phase 1: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)
Seli-Kd
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.
Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Multiple Locations
ClinicalTrials.gov Identifier: NCT02199665
Official Title: A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
First Posted: July 24, 2014
Click here to see details on ClinicalTrials.gov
Drug: selinexor
Drug: carfilzomib
Drug: dexamethasone
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Br J Haematol; 2019
Locations
United States, Arizona
United States, Illinois
United States, Michigan
United States, New York